Literature DB >> 11739902

Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies.

T Völkel1, T Korn, M Bach, R Müller, R E Kontermann.   

Abstract

Bispecific single-chain diabodies (scDb) consist of the variable heavy and light chain domains of two antibodies connected by three linkers. The structure of an scDb in the V(H)-V(L) orientation is V(H)A-linkerA-V(L)B-linkerM-V(H)B-linkerB-V(L)A, with linkers A and B routinely chosen to be 5-6 residues and linker M 15-20 residues. Here, we applied display of scDb on filamentous phage to analyse the composition of optimal linker sequences. The three linkers were randomized in length and sequence using degenerated triplets coding for only six hydrophilic or aliphatic amino acids (Thr, Ser, Asp, Asn, Gly, Ala). Antigen-binding clones were then isolated by one to two rounds of selection on the two different antigens recognized by the bispecific scDb. Using an scDb directed against carcinoembryonic antigen (CEA) and beta-galactosidase (Gal), we found that monomeric scDb had a preferred length of 15 or more amino acid residues for the middle linker M and of 3-6 residues for the linkers A and B. No obvious bias towards a preferred linker sequence was observed. Reduction of the middle linker below 13 residues led to the formation of dimeric scDb, which most likely results from interchain pairing between all the V(H) and V(L) domains. Dimeric scDb were also formed by fragments possessing a long linker M and linkers A and B of 0 or 1 residue. We assume that these dimeric scDb are formed by intrachain pairing of the central variable domains and interchain pairing of the flanking variable domains. Thus, the latter molecules represent a novel format of bispecific and tetravalent molecules. The described strategy allows for the isolation of both optimized and minimal linker sequences for the assembly of monomeric or dimeric single-chain diabodies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739902     DOI: 10.1093/protein/14.10.815

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  12 in total

Review 1.  Generation and production of engineered antibodies.

Authors:  Sergey M Kipriyanov; Fabrice Le Gall
Journal:  Mol Biotechnol       Date:  2004-01       Impact factor: 2.695

2.  Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody.

Authors:  Ryutaro Asano; Keiko Ikoma; Yukiko Sone; Hiroko Kawaguchi; Shintaro Taki; Hiroki Hayashi; Takeshi Nakanishi; Mitsuo Umetsu; Yu Katayose; Michiaki Unno; Toshio Kudo; Izumi Kumagai
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

3.  Homology modelling and bivalent single-chain Fv construction of anti-HepG2 single-chain immunoglobulin Fv fragments from a phage display library.

Authors:  Ming Ni; Bing Yu; Yu Huang; Zhenjie Tang; Ping Lei; Xin Shen; Wei Xin; Huifen Zhu; Guanxin Shen
Journal:  J Biosci       Date:  2008-12       Impact factor: 1.826

Review 4.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

5.  Detection of salinomycin and lasalocid in chicken liver by icELISA based on functional bispecific single-chain antibody (scDb) and interpretation of molecular recognition mechanism.

Authors:  Yingxian Chen; Kunxia Zhao; Jingjie Huang; Miao Li; Xiaojuan Sun; Jiancheng Li
Journal:  Anal Bioanal Chem       Date:  2021-10-18       Impact factor: 4.142

6.  Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse-Methamphetamine and 3,4-methylenedioxymethamphetamine.

Authors:  Reha Celikel; Eric C Peterson; S Michael Owens; Kottayil I Varughese
Journal:  Protein Sci       Date:  2009-11       Impact factor: 6.725

7.  Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine.

Authors:  Eric C Peterson; Elizabeth M Laurenzana; William T Atchley; Howard P Hendrickson; S Michael Owens
Journal:  J Pharmacol Exp Ther       Date:  2008-01-11       Impact factor: 4.030

Review 8.  The making of bispecific antibodies.

Authors:  Ulrich Brinkmann; Roland E Kontermann
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

Review 9.  Applications of SNAP-tag technology in skin cancer therapy.

Authors:  Eden Rebecca Padayachee; Henry Ademola Adeola; Jennifer Catherine Van Wyk; Fleury Augustine Nsole Biteghe; Shivan Chetty; Nonhlanhla Patience Khumalo; Stefan Barth
Journal:  Health Sci Rep       Date:  2019-01-08

Review 10.  The Application of Nanobody in CAR-T Therapy.

Authors:  Chaolemeng Bao; Quanli Gao; Lin-Lin Li; Lu Han; Bingxiang Zhang; Yijin Ding; Zongpei Song; Ruining Zhang; Jishuai Zhang; Xian-Hui Wu
Journal:  Biomolecules       Date:  2021-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.